A method for constructing an animal model of autoimmune aplastic anemia induced by autologous CD34 CAR-T cells.
By genetically engineering T cells to express CARs targeting the CD34 antigen, an autologous CD34 CAR-T cell-induced aplastic anemia animal model was constructed. This solved the problem that existing models could not accurately simulate human autoimmune attack, and achieved a highly consistent and reliable experimental platform, supporting in-depth research and drug evaluation.
Patent Information
- Application Number
- CN202611218428.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-12
- Publication Date
- 2026-11-17
AI Technical Summary
Existing animal models of aplastic anemia cannot accurately simulate the pathogenesis of human immune system attacking autologous hematopoietic stem cells, resulting in inaccurate experimental results and poor model consistency, making it difficult to support in-depth research and drug evaluation.
By genetically modifying the T cells of experimental animals to express chimeric antigen receptors (CARs) targeting the CD34 antigen, and then reinfusing them into the animals, an autologous CD34 CAR-T cell-induced aplastic anemia animal model was constructed to simulate the process of autoimmune bone marrow failure.
A model that closely matches human autoimmune aplastic anemia has been established, improving the reliability and reproducibility of the model, providing a stable experimental platform, and supporting long-term research and drug evaluation.
Smart Images

Figure CN123100564A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology, specifically relating to a method for constructing an animal disease model, particularly a method for inducing the establishment of an animal model of aplastic anemia using autoreactive CAR-T cells targeting the CD34 antigen. Background Technology
[0002] Aplastic anemia (AA) is a syndrome of bone marrow hematopoietic failure caused by various etiologies. It is characterized by decreased bone marrow hematopoietic cell proliferation and pancytopenia in peripheral blood, and clinical manifestations include symptoms such as anemia, bleeding, and infection.
[0003] Currently, the treatment of aplastic anemia mainly includes two strategies: hematopoietic stem cell transplantation (HSCT) and immunosuppressive therapy (IST). For young patients with suitable donors, HSCT is the only curative treatment, with a long-term survival rate of 60%-80%. However, due to limitations in donor matching, patient age, and transplant-related complications, only a small number of patients can benefit from it. For patients who are not suitable for transplantation, IST is the standard treatment, achieving hematologic remission in approximately 60-70% of patients. However, the initial IST treatment failure rate is about 30%, and 10%-20% of effective patients experience relapse. Long-term follow-up shows that 15%-40% of patients may be at risk of clonal evolution. In addition, IST has a slow onset of action, requires frequent blood transfusions during treatment, has high treatment costs, and carries a high risk of infection.
[0004] In recent years, the introduction of thrombopoietin receptor agonists, such as eltrombopag, has brought a breakthrough to the treatment of AA. Studies have shown that eltrombopag combined with IST as first-line treatment can increase the 6-month complete response rate to 58%, significantly better than the traditional IST regimen. However, even with the new combination regimen, a large number of patients still do not respond to treatment. In addition, because its mechanism of action is not yet fully understood, most of these treatments are still in the preclinical or early clinical stages.
[0005] In summary, existing clinical treatment protocols have significant shortcomings in terms of efficacy durability, broad applicability, and drug safety. The development of new therapeutic drugs and intervention strategies is urgently needed, and reliable, stable animal models with mechanisms closely aligned with clinical practice are the core prerequisites for achieving breakthroughs in basic research on aplastic anemia and efficient translation of new drugs.
[0006] Therefore, despite the continuous advancements in AA treatment, existing therapies still have significant gaps in terms of efficacy durability, safety, and accessibility. The development of novel therapeutic drugs and intervention strategies is urgently needed, and providing an accurate, reliable, and stable animal model that simulates the pathological mechanisms of human diseases has become one of the important breakthroughs for in-depth research into the pathogenesis.
[0007] Currently, the commonly used animal models of acquired aplastic anemia in the industry are mainly divided into three categories: physical induction models, chemical induction models, and immune-mediated models.
[0008] Physical methods use radioactive materials (such as...) 60 Irradiation with Co-γ rays induces bone marrow failure by damaging DNA. However, the dosage for modeling is difficult to control precisely, and it differs greatly from the immune-mediated pathological process of human aplastic anemia. As a result, the clinical translational value of the experimental results is extremely low.
[0009] Chemically induced models are simple to operate and low in cost, but the modeling mechanism is mainly based on the direct cytotoxicity of drugs, completely lacking the key link of abnormal activation of autoimmune cells and specific attack on hematopoietic stem cells, which is inconsistent with the nature of human diseases.
[0010] Immune-mediated models are currently the optimal approach for mechanistic simulation. Among these, the allogeneic immune challenge model involves using DBA / 2 mice (H-2... d 1×10 thymus and lymph node cell suspensions (MLSa) 6 (each animal) administered via tail vein at a sublethal dose 60 BALB / c mice (H-2) were irradiated whole-body with Co-γ rays (5.0-6.0 Gy). b However, it still has significant inherent limitations: the model animals usually die within 12-14 days, limiting long-term treatment observation; the model has allogeneic immune responses and cannot accurately simulate the pathogenesis of damage to hematopoietic stem cells by abnormal activation of the human immune system.
[0011] In summary, existing animal models of aplastic anemia generally have significant technical limitations, failing to simulate the core pathogenesis process of human reactive T cells specifically targeting and killing autologous hematopoietic stem cells, which seriously affects their accuracy and reliability in disease mechanism research and drug efficacy evaluation. Summary of the Invention
[0012] Based on the background art, existing aplastic anemia models cannot simulate the pathogenesis of human autoimmune diseases and have obvious problems such as inconsistent mechanisms, poor consistency, and inaccurate evaluation. This invention provides a method for constructing an animal model of aplastic anemia that is targeted, consistent in mechanism, stable and reliable. At the same time, it clarifies the application of autoreactive CAR-T cells targeting CD34 in the construction of this model, providing a reliable experimental carrier for the study of the pathogenesis of aplastic anemia, screening of new therapeutic drugs, and evaluation of drug efficacy.
[0013] Specifically, the core of the technical solution of this invention lies in using genetic engineering to modify the T cells of experimental animals, enabling them to target and attack their own hematopoietic stem cells, thereby simulating the process of autoimmune bone marrow failure in vivo.
[0014] The first objective of this invention is to provide a method for constructing an animal model of autoimmune aplastic anemia induced by autologous CD34 CAR-T cells, the method comprising the following steps: a) Isolate autologous T lymphocytes from the target experimental animal; b) Genetically modify the autologous T lymphocytes in vitro to express a chimeric antigen receptor (CAR) that targets the CD34 antigen, thereby obtaining autoreactive CAR-T cells that target CD34. c) The autoreactive CAR-T cells targeting CD34 were administered at a rate of 1 × 10⁻⁶. 6 Up to 1×10 7 The dose per animal is autologously reinfused into the target experimental animal; d) Continuously monitor the peripheral blood and bone marrow morphology of the target experimental animals. When the target experimental animals show persistent pancytopenia and bone marrow hematopoietic failure, the successful construction of the autoimmune aplastic anemia animal model is confirmed.
[0015] Specifically, the target experimental animal is a rat or mouse, preferably an SD rat.
[0016] Furthermore, in step a), the autologous T lymphocytes are derived from the peripheral blood, spleen, or lymph nodes of the target experimental animal.
[0017] Step a) also includes the purification and activation of the isolated autologous T lymphocytes: T cells are purified using anti-CD3 magnetic bead positive selection, making CD3... + Cell proportion ≥95%; T cells were activated using anti-CD3 / CD28 monoclonal antibody combined with IL-2, thereby increasing CD3... + CD25 + Cell percentage ≥70%.
[0018] In step b), the chimeric antigen receptor comprises, from extracellular to intracellular, a single-chain antibody fragment that specifically recognizes the CD34 antigen, a hinge region, a transmembrane domain, a co-stimulatory signaling domain, and a T-cell activation signaling domain.
[0019] In particular, the transmembrane domain in step b) is selected from the transmembrane region of CD8α; the co-stimulatory signaling domain is selected from the intracellular signaling domain of CD28 or 4-1BB; and the T cell activation signaling domain is the intracellular signaling domain of the CD3ζ chain.
[0020] Furthermore, in step b), the gene modification is performed via lentiviral transduction, with an infection multiplicity of 5-10, and the transduction is carried out in a culture dish coated with RetroNectin. In step c), the autologous reinfusion is performed via tail vein injection. In a preferred embodiment, the tail vein injection rate is 80 μL / min, and in another preferred embodiment, the tail vein injection rate is 120 μL / min. Prior to reinfusion, it must be confirmed that the CAR-T cell viability is ≥85%.
[0021] Preferably, as confirmed by preferred embodiments, in step c), the number of reinfused cells is limited to 1×102 6 Up to 1×10 7 Using one animal per animal can effectively improve the controllability of model induction efficiency and the consistency of model severity, and greatly help the reproducibility and standardization of the method.
[0022] In step d), the peripheral blood morphology monitoring includes white blood cell count, red blood cell count, hemoglobin content, and platelet count; the bone marrow morphology monitoring includes the number of nucleated cells in the bone marrow and CD34 count. + The proportion of hematopoietic stem cells and the pathological morphology of bone marrow.
[0023] Furthermore, the method for constructing an autoimmune aplastic anemia animal model induced by autologous CD34 CAR-T cells described in this invention results in a persistent pancytopenia in the model animals, with white blood cell, red blood cell, and platelet counts decreasing by ≥50% for two consecutive weeks or more compared to before modeling.
[0024] A second objective of this invention is to provide the use of CD34-targeting autoreactive CAR-T cells in the preparation of formulations for constructing animal models of autoimmune aplastic anemia.
[0025] Specifically, the CD34-targeting autoreactive CAR-T cells are obtained by genetically modifying autologous T lymphocytes of the target experimental animal to express a CAR targeting the CD34 antigen; the CAR-T cells are then processed at a rate of 1×10⁻⁶. 6 ~1×10 7 The dose per animal is autologously reinfused into the target experimental animal to induce bone marrow hematopoietic failure.
[0026] The working principle of this invention is as follows: First, autologous T lymphocytes are isolated from the target experimental animal and modified using genetic engineering techniques to express a chimeric antigen receptor (CAR) targeting the CD34 antigen on the surface of the T cells. This CAR can specifically recognize the CD34 antigen on the surface of hematopoietic stem cells. The successfully constructed autoreactive CAR-T cells targeting CD34 are then autologously reinfused into the original donor animal at a standardized dose, avoiding interference from allogeneic immune rejection. This allows the CAR-T cells to specifically recognize and bind to the animal's own CD34 antigen in vivo. +Hematopoietic stem cells are then activated, thereby activating the killing function of T cells to continuously attack and destroy hematopoietic stem cells. With the extensive damage to hematopoietic stem cells, the hematopoietic function of the animal's bone marrow gradually fails, eventually exhibiting typical pathological features of aplastic anemia such as persistent pancytopenia and bone marrow hypoplasia, thus achieving the construction of an animal model that is highly consistent with the pathogenesis of human autoimmune aplastic anemia.
[0027] Compared with the prior art, the present invention achieves the following significant technical effects: (1) The model constructed in this invention uses autoreactive CAR-T cells to target and kill autologous CD34 cells. + Using hematopoietic stem cells as the core, this study closely matches the pathogenesis of human autoimmune aplastic anemia and can accurately reflect the therapeutic effects of drugs on autoimmune aplastic anemia, providing a more clinically relevant and reliable experimental platform for the study of the pathogenesis of aplastic anemia.
[0028] (2) This invention limits the key modeling steps such as T cell purification and activation standards, CAR-T cell transduction parameters, and reinfusion dose, making the model construction process more standardized. The success rate of modeling and the reproducibility of experimental results are much higher than those of traditional models, meeting the standardized experimental requirements of basic research and drug development. (3) The modeling ideas of this invention are not only applicable to the construction of an animal model of autoimmune aplastic anemia induced by autologous CD34 CAR-T cells, but can also be extended to the construction of models of other organ-specific autoimmune diseases, providing new technical ideas and methods for the overall research of autoimmune diseases. (4) The model constructed in this invention solves the problem of short-term lethality of the non-allogeneic immune model commonly used in the prior art. The animals exhibit persistent pathological features of aplastic anemia and provide a sufficient experimental time window for the study of the chronic course of aplastic anemia, evaluation of long-term treatment plans, and observation of the effects of combined drug treatment, thus solving the technical limitation of the short observation window of the existing model. Attached Figure Description
[0029] Figure 1 This is a schematic diagram of the method flow of the present invention; Figure 2 This is a schematic diagram illustrating the mechanism of action of the self-reactive CAR-T cells of the present invention; Figure 3 This is a comparison of pathological sections before and after modeling according to the present invention (left side is before modeling, right side is after modeling). Specific Implementation The present invention will be further described in detail below with reference to specific experimental cases. It should be noted that this embodiment is only used to illustrate the present invention and is not intended to limit the scope of protection of the present invention.
[0031] In this example, SPF grade SD rats are used as experimental animals to elaborate the whole process of preparation and verification of autoreactive CAR-T cells targeting CD34, as well as the construction and stability verification of an autoimmune aplastic anemia animal model. All experimental operations follow aseptic operation specifications, and experimental instruments are used after being calibrated and qualified. For those without specific experimental methods and reagent sources indicated, they are all conventional experimental methods or obtained through commercial purchase. The experiment of the present invention is approved by the Animal Experiment Ethics Committee, and all experimental operations comply with animal ethics requirements.
[0032] The specific description is as follows: Experimental animals: SPF grade SD rats, male, weighing 200±20g, provided by Shandong Pengyue Laboratory Animal Technology Co., Ltd., Animal Certificate No.: SCXK(Lu)20220006. The experimental animals are reared in a barrier environment animal room, with free access to drinking water and food during the period, the temperature is controlled at 22±2℃, the humidity is 50±5%, and the light and dark alternate for 12 hours.
[0033] Experimental reagents and consumables: Ficoll density gradient centrifugation solution (Cytiva), RPMI1640 medium (Gibco), fetal bovine serum (FBS, special grade, Gibco), penicillin-streptomycin (P / S, 100×, Gibco) double antibody, recombinant human interleukin-2 (IL-2) (PeproTech); anti-mouse CD3 magnetic beads (Miltenyi Biotec), anti-CD3 / CD28 monoclonal antibody pre-coated culture dishes (Corning); third-generation self-inactivating lentiviral vector (constructed by this laboratory), RetroNectin (recombinant fibronectin fragment) (Takara Bio); lactate dehydrogenase (LDH) cytotoxicity detection kit (Promega); May-Giemsa staining solution (Solarbio), HE staining solution (Beyotime); automated hematology analyzer (Sysmex, XN-1000), flow cytometer (BD Biosciences, FACSAria III), inverted microscope (Olympus, IX73), constant temperature CO₂ incubator (Thermo Fisher, Forma 3111).
[0034] Target cell lines: K562 cell line (human leukemia cell line) (introduced from the Cell Bank of the Chinese Academy of Sciences and preserved in the laboratory), the K562-CD34 target cell line expressing mouse CD34 protein is constructed via gene transfection (constructed by this laboratory, with a CD34 positive expression rate of ≥95% verified by flow cytometry), wild-type K562 cells are used as negative control; normal rat fibroblasts and hepatocytes are used as control cells for off-target toxicity detection.
[0035] Experimental Groups: Fifteen SD rats were randomly divided into three groups of five rats each, as follows: Blank control group (Group A): No treatment was given, and the animals were fed normally. Sham surgery control group (Group B): The same volume of 0.9% saline was injected via the tail vein as the experimental group, and the rest of the operation was the same as the experimental group; Experimental group (Group C): An animal model of autoimmune aplastic anemia was constructed using the method of this invention, and 1×10⁻⁶ cells were reinfused via the tail vein. 6 One / each autoreactive CAR-T cell targeting CD34.
[0036] Example 1: Preparation and validation of CD34-targeting autoreactive CAR-T cells This embodiment completes the isolation, purification, activation, and gene modification of CD34-targeting autoreactive CAR-T cells, and verifies their specific killing ability and lack of off-target toxicity through in vitro functional experiments, ensuring that the prepared CAR-T cells meet the requirements for modeling experiments.
[0037] 1.1 Isolation, purification and activation of autologous T lymphocytes Isolation: 2-3 mL of anticoagulated blood (heparin sodium anticoagulation, final concentration 10 U / mL) was collected from the peripheral blood of each SD rat in the experimental group. After blood collection, Ficoll density gradient centrifugation was performed at 400×g, 20 min, and room temperature to collect the intermediate mononuclear cell layer. The cells were washed three times with RPMI 1640 medium containing 5% FBS and 1% P / S, and the cell concentration was adjusted to 1×10⁻⁶ cells / mL. 6 per mL.
[0038] It is worth noting that the time interval between blood collection and the subsequent centrifugation step can significantly affect the subsequent cell viability. A preferred embodiment has confirmed that centrifugation should be performed within 4 hours after blood collection, at which point cell viability is ≥90%. In this experiment, centrifugation was performed immediately after blood collection.
[0039] Purification: Magnetic bead selection was used. Magnetic beads coated with anti-mouse CD3 monoclonal antibody were mixed with the cell suspension and incubated at room temperature for 15 minutes to allow the antibody to bind to the surface CD3 antigen. The mixture was then placed on a magnetic rack to adsorb the magnetic beads. Non-T cells in the supernatant were discarded. After washing three times with culture medium, the magnetic beads were released to obtain purified T cells.
[0040] Purification result verification: CD3 count of purified cells was detected by flow cytometry. + Positive rate, results showed CD3 + The cell ratio is ≥95%, meeting the experimental purification requirements, and can be used for subsequent activation experiments.
[0041] Activation and proliferation: Purified T cells were injected at a dose of 1×10⁻⁶. 6 Inoculate the culture dish containing anti-CD3 / CD28 monoclonal antibody at a density of 1000 U / mL, add IL-2 to the culture medium to a final concentration of 1000 U / mL, and place in a 37°C, 5% CO2 incubator. Replace the culture medium containing fresh IL-2 every 2 days.
[0042] Activation result verification: Cell morphology was observed under a microscope daily, and cell count was performed every 24 hours using a hemocytometer; CD3 count was performed by flow cytometry on day 3 of culture. + CD25 + The positive rate is ≥70%, and the cell viability detected by the blood cell counter is ≥95%; under the microscope, T cells are rounded and aggregated, showing a typical activated morphology, which meets the activation standard and can be used for subsequent gene modification experiments.
[0043] Proliferation characteristics: The doubling time of activated T cells is 36-48 hours, and the number of cells doubles every 1.5-2 days, which is consistent with the normal proliferation pattern of T cells.
[0044] 1.2 CAR gene construction and lentiviral vector preparation Introducing a CD34-targeting CAR gene into T cells enables T cells to express specific CD34-recognizing and killing genes. + CAR is a fusion protein of cells. Its structure consists of three parts from the outside in: (1) Extracellular recognition domain: single-chain antibody (scFv), evolved from anti-CD34 antibody, with sufficient affinity (KD<10). -7 M) and specificity. It is obtained by screening through phage display libraries or by modifying monoclonal antibodies. It is about 130 amino acids in length and can specifically recognize CD34 protein.
[0045] (2) Transmembrane domain: The CD8α constant region is used to stably anchor CAR to the cell membrane.
[0046] (3) Intracellular signaling domain: Second-generation CAR includes: The main activation signal is the ITAM region of the CD3ζ chain, which triggers the T cell receptor signaling pathway after recognizing a target cell.
[0047] Co-stimulatory signals: The intracellular domains of CD28 or 4-1BB provide a second signal, enhancing T cell activation and persistence. The complete CAR sequence was designed as follows: signal peptide - anti-mouse CD34 single-chain antibody fragment (scFv) - IgG1 - Fc hinge region - CD8α transmembrane region - CD28 co-stimulatory signal domain - CD3ζ activation signal domain. The complete CAR gene sequence was cloned into a third-generation self-inactivated lentiviral vector, and lentivirus was produced using a specialized viral preparation platform, with titer testing confirming it met the required standard (titer ≥ 1 × 10⁻⁶). 8 (TU / mL) and then set aside.
[0048] 1.3 Lentiviral transduction for CAR-T cell preparation Preparation before transduction: Add RetroNectin at a concentration of 250 μg / mL to the culture plate and incubate overnight at 4°C to ensure uniform protein distribution, thereby increasing the contact efficiency between viral particles and the surface of T cells.
[0049] It should be noted that the culture plate was washed with PBS before transduction to remove unbound RetroNectin, thereby increasing the contact efficiency between viral particles and T cells and improving transduction efficiency. The plate was washed three times.
[0050] Lentiviral transduction: The activated T cells described above were transduced at a rate of 5 × 10⁶. 5 Cells were seeded in wells and lentiviral solution was added to achieve a multiplicity of infection (MOI) of 5-10. After incubation at 32°C for 8 hours, the cells were transferred to a 37°C, 5% CO2 incubator for further culture. After 24 hours of transduction, the medium was replaced with RPMI medium containing fresh IL-2 for amplification to remove exogenous virus. The medium was changed every 2 days.
[0051] CAR expression detection: On days 3-5 after transduction, a portion of cells were taken and the CAR positive expression rate was detected by flow cytometry. The positive rate was ensured to reach 70%-80% to meet the experimental requirements. The remaining cells were cultured and expanded for subsequent modeling experiments.
[0052] 1.4 In vitro functional validation of CAR-T cells Cytotoxicity verification: The prepared CAR-T cells were used as effector cells, K562-CD34 cells as target cells, and wild-type K562 cells as negative controls. They were seeded in U-shaped bottom microplates at an effector cell:target cell ratio of 5:1 and co-cultured for 4 h. At the same time, a pure K562-CD34 cell control group and a pure CAR-T cell control group were set up. The cell lysis rate was detected by an LDH detection kit.
[0053] The results showed that the lysis rate of CAR-T cells against K562-CD34 target cells was ≥60%, while the lysis rate against wild-type K562 cells was <10%, indicating that CAR-T cells have a specific killing ability against CD34 antigen.
[0054] Off-target toxicity verification: CAR-T cells were co-cultured with normal rat fibroblasts and hepatocytes for 24 h, and the survival rate of normal cells was detected.
[0055] The results showed that the survival rate of target cells was ≥90%, indicating that CAR-T cells had no significant non-specific off-target killing effect.
[0056] 1.5 Expansion and Quality Assay of CAR-T Cells The validated CAR-T cells were further expanded in a medium containing 1000 U / mL IL-2 until day 15 of culture. Cells were then collected and subjected to quality testing, and the results met the experimental requirements. (1) The CAR positivity rate detected by flow cytometry is maintained above 70%; (2) The cell viability detected by blood cell counter is ≥90%; (3) The aseptic culture test shows no contamination by Gram-positive or Gram-negative bacteria; (4) The endotoxin test result is <100EU / L.
[0057] CAR-T cells that passed quality testing were suspended in 0.9% physiological saline, and the cell concentration was adjusted to 1×10⁻⁶. 6 Store at 100 μL per sample, at 4°C for later use in animal model construction. Example 2: Construction of an animal model of autoimmune aplastic anemia induced by autologous CD34 CAR-T cells In this embodiment, qualified CD34-targeting autoreactive CAR-T cells were prepared by tail vein infusion to complete the construction of an animal model of autoimmune aplastic anemia. The success of the model construction was verified by dynamic monitoring of peripheral blood and bone marrow morphology and analysis of pathological characteristics, and the consistency between the pathological characteristics of the model and autoimmune aplastic anemia was clarified.
[0058] 2.1 Autologous tail vein infusion of CAR-T cells The CD34-targeting autoreactive CAR-T cells prepared in Example 1 were collected by centrifugation 4 hours before reinfusion, resuspended in 0.9% saline, and accurately counted using a hemocytometer, adjusted to 1×10⁻⁶ cells. 7 A dose of 1 cell per cell was administered, and the final cell viability was measured to be ≥85%.
[0059] SD rats in the experimental group were briefly anesthetized, and the skin around the tail vein was disinfected. The tail vein was punctured using a 27G fine needle, and CAR-T cell suspension was slowly injected at a rate of 100 μL / min. After the injection, the rats were observed for 10 minutes. Only rats that showed normal activity and no abnormal reactions such as convulsions or bleeding were returned to their cages.
[0060] The blank control group received no treatment. The sham-operated control group received an equal volume of 0.9% saline via tail vein injection, with all other procedures identical to the experimental group. The reinfusion time, cell count, and activity were accurately recorded for each group of rats.
[0061] 2.2 Monitoring of Indicators After Model Construction All three groups of rats were cultured under the same feeding conditions. Peripheral blood and bone marrow morphology were monitored regularly from the day of CAR-T cell infusion (referred to as day 0). The monitoring time and detection methods of the blank control group and sham-operated control group were completely consistent with those of the experimental group.
[0062] Peripheral blood count monitoring: Blood was collected at three time points each week (Monday, Wednesday, and Friday). In this study, blood was collected from the retro-orbital venous plexus. 50-100 μL of anticoagulated blood (EDTA anticoagulated) was collected from each rat, and the white blood cell count (WBC), red blood cell count (RBC), hemoglobin content (Hb), and platelet count (PLT) were immediately measured using a fully automated blood analyzer. The data were recorded, and blood count change curves were plotted.
[0063] Bone marrow morphology monitoring: Bone marrow morphology was performed on rats in each group on days 7, 14, and 21 after reinfusion. After anesthesia, 100-200 μL of bone marrow fluid was extracted from the distal femur using a sterile needle for the following analysis: Prepare a smear from a portion of bone marrow fluid, air-dry it, stain it with May-Giemsa stain, fix, rinse, and dry it according to standard procedures; observe the number, morphology, and CD34 count of nucleated cells in the bone marrow under an inverted microscope. + The proportion of hematopoietic stem cells was determined; a portion of bone marrow fluid was taken, fixed, dehydrated, embedded, and then prepared into paraffin sections for HE staining. The pathological morphological changes of bone marrow were observed under an inverted microscope, and the ratio of hematopoietic tissue to adipocytes was analyzed.
[0064] 2.3 Determination of successful model construction Based on the clinicopathological characteristics of autoimmune aplastic anemia, the criteria for determining the successful establishment of the animal model of this invention are formulated. The model must simultaneously meet the characteristics of peripheral blood and bone marrow morphology, and the indicators must not show a spontaneous recovery trend. Specifically, the following characteristics should be met to determine that the animal model of autoimmune aplastic anemia has been successfully established: (1) Peripheral blood characteristics: For two consecutive weeks or more, the white blood cell count, red blood cell count, and platelet count decreased by ≥50% compared with the baseline level before modeling, and the hemoglobin content decreased significantly at the same time; the peripheral blood indicators of rats in the blank control group and sham operation control group did not fluctuate significantly throughout the process and remained at normal levels.
[0065] (2) Bone marrow characteristics: The number of nucleated cells in the bone marrow is significantly reduced, and CD34 is low. +The proportion of hematopoietic stem cells decreased significantly, by ≥70% compared to baseline; microscopic examination of bone marrow smears revealed decreased hematopoietic tissue proliferation, increased adipocyte ratio, and a tendency for the bone marrow cavity to become empty, consistent with the typical pathological features of bone marrow hematopoietic failure; the bone marrow morphology of rats in the blank control group and sham-operated control group was normal, with active hematopoietic tissue proliferation and CD34 levels. + The proportion of hematopoietic stem cells remains within the normal range.
[0066] In this experiment, all five SD rats in the experimental group met the above criteria in the third week after CAR-T cell infusion, and the model construction success rate was 100%. Moreover, after the model was successfully constructed, the rats did not experience short-term death and could maintain the pathological characteristics of aplastic anemia. The experimental observation window was sufficient to meet the experimental needs of subsequent pathogenesis research, drug screening, and other experiments.
[0067] Example 3: Stability and Repeatability Verification of the Model To verify the stability and reproducibility of the model constructed by the method of the present invention, and to overcome the defects of traditional modeling methods such as poor model consistency, large fluctuation in modeling rate, and significant batch-to-batch deviation, the modeling experiment was repeated for three batches according to the same experimental methods, experimental parameters, and judgment criteria as in Examples 1 and 2. Each batch included a blank control group, a sham-operated control group, and an experimental group (5 SD rats in each group).
[0068] All three batches of experiments used 8-10 week old, same-batch, weight-matched SPF-grade SD rats (200±20g). CAR-T cells were prepared and packaged from the same batch, and the quality test data were consistent (CAR positivity rate of batch 1: 76.8%±2.5%, batch 2: 75.2%±3.1%, batch 3: 74.5%±2.8%; one-way ANOVA showed no significant difference, P>0.05). All experimental reagents, consumables, and instruments were from the same batch / calibrated state, and all operations were performed by the same personnel, strictly controlling experimental variables to ensure the comparability of experimental results.
[0069] Statistical analysis was conducted on the modeling efficiency, modeling time, and core pathological indicators of three batches of experiments, and the stability and reproducibility of the model were verified through specific numerical values.
[0070] The statistical results of modeling efficiency and modeling time in the three batches of experiments are shown in Table 1. There were no significant differences between the batches (P>0.05). The specific values are shown in Table 1. Table 1. Success rate and molding time for each batch and group. The results show that the average modeling time for the three batches of experiments was 20±1 days, the difference in modeling time between batches was ≤3 days, and the difference in modeling time within a single batch of rats was ≤3 days. The differences were due to fluctuations in normal individuals in the experiment and were not statistically significant. This indicates that the modeling efficiency of the modeling method of the present invention is stable and the modeling time is highly reproducible.
[0071] The core peripheral blood indicators of rats in each group, WBC, RBC, HGB, and PLT, decreased by ≥50% compared with the data before modeling, and there were no significant differences in each indicator between batches (P>0.05). The results are shown in Table 2.
[0072] Table 2. Results of stability verification of peripheral blood parameters When the experimental group rats met the criteria for model establishment, the core pathological indicators of bone marrow morphology were consistent with the characteristics of hematopoietic failure, and there were no significant differences in various indicators between batches (P>0.05). The results are shown in Table 3.
[0073] Table 3. Results of Stability Verification of Core Pathological Indicators in Bone Marrow Phenotypes In the experiment, the bone marrow of rats in the experimental group showed typical pathological features of aplastic anemia, including extremely low hematopoietic tissue proliferation and emptying of the bone marrow cavity. The bone marrow morphology of the blank control group and the sham-operated control group was normal throughout the experiment, with no hematopoietic failure-related manifestations.
[0074] By day 42, none of the rats that had developed the model experienced short-term death. Their mental state and feeding ability were not significantly abnormal. Peripheral blood and bone marrow morphology still maintained the pathological characteristics of aplastic anemia, with no spontaneous recovery trend.
[0075] The peripheral blood and bone marrow morphology indicators of both the blank control group and the sham surgery control group showed no significant fluctuations and maintained normal physiological levels, further confirming that the model of this invention is based on the specific biological effects of CAR-T cells, rather than normal physiological fluctuations or experimental interference.
[0076] In summary, the method for constructing an autologous CD34 CAR-T cell-induced autoimmune aplastic anemia animal model of the present invention has a high degree of standardization, strong reproducibility of experimental results, and good model stability. It overcomes the defects of traditional modeling methods and can serve as an ideal animal model carrier platform for studying the pathogenesis of autoimmune aplastic anemia, screening new targeted drugs, and evaluating their efficacy.
Claims
1. A method for constructing an animal model of autoimmune aplastic anemia induced by autologous CD34 CAR-T cells, characterized in that, Includes the following steps: a) Isolate autologous T lymphocytes from the target experimental animal; b) Genetically modify the autologous T lymphocytes in vitro to express a chimeric antigen receptor (CAR) that targets the CD34 antigen, thereby obtaining autoreactive CAR-T cells that target CD34. c) The autoreactive CAR-T cells targeting CD34 were administered at a rate of 1 × 10⁻⁶. 6 Up to 1×10 7 The dose per animal is autologously reinfused into the target experimental animal; d) Continuously monitor the peripheral blood and bone marrow morphology of the target experimental animals. When the target experimental animals show persistent pancytopenia and bone marrow hematopoietic failure, the successful construction of the autoimmune aplastic anemia animal model is confirmed.
2. The construction method according to claim 1, characterized in that, The target experimental animal is a rat or mouse, preferably an SD rat.
3. The construction method according to claim 1, characterized in that, In step a), the autologous T lymphocytes are derived from the peripheral blood, spleen, or lymph nodes of the target experimental animal; more preferably, step a) further includes a step of purifying and activating the isolated autologous T lymphocytes: purifying the T cells using an anti-CD3 magnetic bead positive selection method, so that CD3... + Cell proportion ≥95%; T cells were activated using anti-CD3 / CD28 monoclonal antibody combined with IL-2, thereby increasing CD3... + / CD25 + Cell percentage ≥70%.
4. The construction method according to claim 1, characterized in that, In step b), the chimeric antigen receptor comprises, from extracellular to intracellular, a single-chain antibody fragment that specifically recognizes the CD34 antigen, a hinge region, a transmembrane domain, a co-stimulatory signaling domain, and a T-cell activation signaling domain.
5. The construction method according to claim 5, characterized in that, The transmembrane domain is selected from the transmembrane region of CD8α; the co-stimulatory signaling domain is selected from the intracellular signaling domain of CD28 or 4-1BB; and the T cell activation signaling domain is the intracellular signaling domain of the CD3ζ chain.
6. The construction method according to claim 1, characterized in that, In step b), the gene modification is performed by lentivirus transduction, and the multiplicity of infection used during transduction is 5-10; in step c), the autologous reinfusion is performed by tail vein injection.
7. The construction method according to claim 1, characterized in that, In step d), the peripheral blood morphology monitoring includes white blood cell count, red blood cell count, hemoglobin content, and platelet count; the bone marrow morphology monitoring includes the number of nucleated cells in the bone marrow and CD34 count. + The proportion of hematopoietic stem cells and the pathological morphology of bone marrow.
8. The construction method according to any one of claims 1 to 7, characterized in that, The term "persistent pancytopenia" is defined as a decrease of ≥50% in white blood cell, red blood cell, and platelet counts for two consecutive weeks or more compared to before the modeling process.
9. Use of an autoreactive CAR-T cell targeting CD34 in the preparation of a formulation for constructing an animal model of autoimmune aplastic anemia.
10. The use according to claim 9, characterized in that, The CD34-targeting autoreactive CAR-T cells were obtained by genetically modifying autologous T lymphocytes from the target experimental animal to express a CAR targeting the CD34 antigen; the CAR-T cells were then used at a rate of 1×102 6 ~1×10 7 The dose per animal is autologously reinfused into the target experimental animal to induce bone marrow hematopoietic failure.
